Table 2.
Response to eculizumab therapy
Variable | OR | P |
---|---|---|
Log (sC5b-9) at TA-TMA diagnosis | 0.28 | .026 |
Log (sC5b-9 max) before starting eculizumab | 0.15 | .0014 |
rUPCR at TA-TMA diagnosis | 0.76 | .65 |
aGVHD diagnosed before TA-TMA* | 0.96 | .95 |
aGVHD diagnosed after TA-TMA*,† | 0.3 | .16 |
The OR is from a univariate logistic regression model with response defined as a CR or a PR. An OR > 1 indicates that the variable corresponds to a decrease in the odds of a response.
aGVHD, acute GVHD.
Analysis excludes autologous HSCT recipients.
Analysis excludes those with aGVHD before TA-TMA.